Some of the cells that guard us from old infections are built to outlast the moment that created them, while others quietly fade, and nobody has yet read the rule that separates them. The National Institutes of Health has now placed $7.2 million behind a Scripps Research laboratory that hopes to learn that rule through a new mouse model that follows antibody-producing plasma cells across their whole lives. The question matters because it touches every vaccine that promises protection for years rather than weeks, and the answer remains, for now, a patient search rather than a finished truth.
$7.2M in NIH Funding Backs Scripps Research Probe into Why Some Plasma Cells Live for Decades
Some vaccines protect for life; others fade and need boosters.
Mark
Why does it matter that some plasma cells last and others don't?
Mimi
Because those long-lived cells are what keep antibodies coming for years. Measles vaccination in childhood can protect for life, but Tdap often needs boosters. Nobody can fully explain the difference yet.
Mark
What's the lab actually doing differently?
Mimi
They built a mouse model that tracks plasma cells across their whole lifespan. They'll timestamp cells made during infection or vaccination at mucosal sites, then follow them with sequencing.
Luke
Let me slow down there. This is mouse work. Nothing in the reporting says it has been tested in people.
Mimi
Right, it's preclinical. The vaccine payoff is described as something that could eventually happen.
Mark
What's the second grant for?
Mimi
The DP2 looks at what plasma cells do beyond antibodies, like producing cytokines and mediators that help keep tissues in balance.
Luke
And the malaria, HIV and dengue point is de Carvalho's own framing. He says cells can be induced but don't last. The piece doesn't offer independent evidence for that.
Mark
Is the collaboration notable?
Mimi
Miguel Reina-Campos at the La Jolla Institute for Immunology will do the spatial transcriptomics, which maps gene activity to places in tissue.
Luke
Whether the team actually finds the longevity signals is unknown. That's the hope, not a result.
El Pulso
- A vaccine that works once but fades is a quiet failure that surfaces only years later, when boosters are needed again.
- Malaria, HIV and dengue vaccines can seemingly coax plasma cells into existence, yet those cells vanish before they can protect anyone for long.
- A new mouse model lets researchers timestamp plasma cells during infection and trace them through their entire lifespan.
- Two NIH grants totaling $7.2 million are now funding a five-year effort to find the signals that tell a cell to endure.
- The work is still preclinical, so its promise for better vaccines remains a horizon rather than a result.
Some of the cells that guard us from old infections are built to outlast the moment that created them, while others quietly fade, and nobody has yet read the rule that separates them. The National Institutes of Health has now placed $7.2 million behind a Scripps Research laboratory that hopes to learn that rule through a new mouse model that follows antibody-producing plasma cells across their whole lives. The question matters because it touches every vaccine that promises protection for years rather than weeks, and the answer remains, for now, a patient search rather than a finished truth.
Two grants from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will support a five-year effort at Scripps Research to understand why some antibody-producing cells last for decades while others disappear. Together they total $7.2 million, a $4.5 million R01 and a $2.7 million DP2, both awarded to assistant professor Renan de Carvalho and his lab.
The cells at the center of the work are plasma cells, which make antibodies that identify and help clear foreign substances. Some mature into long-lived plasma cells that can protect for years or even decades. The pattern is uneven: measles vaccination can protect for life, while the Tdap vaccine often requires boosters. "We don't really understand how to explain these discrepancies," de Carvalho says.
The lab's new mouse model follows plasma cells through their full lifespan, something scientists have long lacked. Under the R01, the team will timestamp cells formed during infection or vaccination at mucosal sites, then track them with high-throughput sequencing, including spatial transcriptomics carried out with collaborator Miguel Reina-Campos of the La Jolla Institute for Immunology. The DP2 award asks a parallel question: what else plasma cells do, such as producing cytokines that help maintain tissue balance.
For malaria, HIV and dengue, the difficulty is that long-lived cells can be induced but do not last. If the rules of longevity can be learned, de Carvalho believes those barriers might be overcome. For now, that remains a hope the science has yet to test.
Two grants from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, will fund a five-year effort at Scripps Research to work out why some of the body's antibody-producing cells last for decades while others disappear. The awards total $7.2 million: a $4.5 million R01 and a $2.7 million DP2. Both go to Renan de Carvalho, an assistant professor at Scripps, and his lab.
The cells in question are plasma cells, the immune cells that make antibodies. Antibodies identify foreign substances and help clear them from the body. Some plasma cells mature into long-lived plasma cells, which persist and keep providing protection for years or even decades. Not every vaccine efficiently produces them, and when one does not, its protection can fade over time.
The pattern is uneven. De Carvalho points to measles, where childhood vaccination can protect for life. The Tdap vaccine, against tetanus, diphtheria and pertussis, is different, and booster doses may be needed. "We don't really understand how to explain these discrepancies," he says. The two grants, in his words, focus on what makes plasma cells last and effectively do their jobs.
The NIH uses the two grant types for different purposes. R01 grants support specific, independent research projects. DP2 grants, also called Director's New Innovator Awards, support early-career scientists pursuing high-risk, high-reward research.
A central obstacle has been the lack of efficient preclinical models. Without them, scientists have struggled to determine which factors drive the "decision" of a plasma cell to become long-lived. De Carvalho's lab developed a mouse model that tracks plasma cells across their entire lifespan, an approach the source describes as promising for answering these questions at high resolution.
Under the R01, the team plans to use that model to "timestamp" plasma cells produced during infection or vaccination at mucosal sites. They will then characterize those cells throughout their lifetimes using several high-throughput sequencing techniques. One of them, spatial transcriptomics, maps gene activity to specific locations in tissue. It will be carried out by collaborator Miguel Reina-Campos, an assistant professor at the La Jolla Institute for Immunology. With the resulting data, the researchers hope to identify the specific signals that instruct a plasma cell to persist.
The DP2 award goes toward a second question: what plasma cells do besides make antibodies. The work will look at their production of immune molecules such as cytokines and mediators, which help maintain balance in different body tissues, across multiple tissues and sites.
The practical stakes are in vaccine design. Many existing vaccines depend on inducing long-lived plasma cells for durable protection. For malaria, HIV and dengue, de Carvalho says, the challenge is that such cells can be induced but do not last. His lab wants to step back and examine the underlying biology of what dictates longevity. If the rules are learned, he says, they may be able to overcome these vaccination barriers. The work is preclinical, so any vaccine applications remain a prospect rather than a result.
Citas Notables
For malaria, HIV and dengue, we can induce these cells, but they don't last.— Renan de Carvalho, Scripps Research
Quieres la nota completa?
Lee el original en News-Medical ↗